Latham & Watkins Advises on Roar BidCo’s Acquisition of Recipharm

Finance and capital markets team acts on private equity firm’s purchase of listed Swedish pharmaceuticals company.

February 19, 2021

Latham & Watkins advised on the financing of EQT’s acquisition, through Roar BidCo, of all tendered shares and convertible bonds in Recipharm, one of the five largest pharmaceutical contract development and manufacturing organizations in the world, with global production facilities.

The acquisition was made through a public offer of SEK232 in cash per share to the shareholders of Recipharm, and SEK1,504,295 in cash per convertible bond, totaling ~US$3 billion (SEK24.93 billion).

Roar BidCo's shareholding in Recipharm now corresponds to approximately 95.1 per cent of the share capital and approximately 98.3 per cent of the voting rights, as well as 100 per cent of the issued convertible bonds.

Financing for the offer was led by London partners Dominic Newcomb and Jennifer Engelhardt, with counsel Will Lam and associates Melanie Emmen and Medha Vikram. Advice on convertible bonds was provided by London capital markets partner Manoj Tulsiani and associate Amina Tsatiashvili.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.